Drugs / Adjuvanted trivalent influenza virus vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00841763 Comparator | Oct 2008 → Apr 2009 | influenza | Novartis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adjuvanted trivalent influenza virus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00841763 ↗ |
| Known as | aTIV | “Adjuvanted trivalent influenza virus vaccine (aTIV)” NCT00841763 ↗ |
| Modality | Vaccine | “MF59-adjuvanted seasonal reference vaccine” PMID 22192847 ↗ Dec 2011 |
| Route | Intramuscular | “Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.” NCT00841763 ↗ |